GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance ... saw sales tumble 72%, its influenza vaccine saw sales slump 24% and its shingles vaccine saw sales weaken by 7%.

It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild ...

Notably, GSK points to the rapid creation of an mRNA vaccine candidate during the 2013 influenza outbreak in China, setting a record for vaccine development time. The scientific journal Nature hig ...

Sales of the influenza vaccine, Fluarix, were down 22%. Sales of Established vaccines improved 10%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed ...

and inactivated trivalent influenza vaccine (TIV; Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to ...

Earlier today, the Food and Drug Administration (FDA) put a clinical hold on the combination and standalone influenza shot developed ... London-based GSK (NYSE:GSK) is up 0.5% to trade at $39. ...

British Drugmaker GSK Moves MRNA Flu Vaccine to Late-stage Trials British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme ...

I'm pleased to report that despite some challenges, this has been a positive quarter for GSK, and we're delivering ... headline data from our mRNA influenza vaccine candidate, demonstrating ...